Cost effectiveness and strategic planning (WHO-CHOICE)

AFR E: Cost effectiveness results for Breast cancer

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2005.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
BRE-1: Stage I treatment 50% 0.02 18% 82% 180 108 108
BRE-2: Stage II treatment 50% 0.02 16% 84% 46 458 Dominated
BRE-3: Stage III treatment 50% 0.04 8% 92% 76 541 Dominated
BRE-4: Stage IV treatment 50% 0.02 17% 83% 2 11,305 Dominated
BRE-5: Treatment all stages 50% 0.06 18% 82% 299 208 Dominated
BRE-6: Optimal program 50% 0.15 24% 76% 1,291 116 117
BRE-7: Stage I treatment 80% 0.03 18% 82% 289 112 Dominated
BRE-8: Stage II treatment 80% 0.03 16% 84% 74 473 Dominated
BRE-9: Stage III treatment 80% 0.07 8% 92% 122 551 Dominated
BRE-10: Stage IV treatment 80% 0.03 17% 83% 3 11,699 Dominated
BRE-11: Treatment all stages 80% 0.10 18% 82% 478 211 Dominated
BRE-12: Optimal program 80% 0.24 24% 76% 2,065 116 118
BRE-13: Stage I treatment 95% 0.04 18% 82% 343 113 Dominated
BRE-14: Stage II treatment 95% 0.04 16% 84% 88 480 Dominated
BRE-15: Stage III treatment 95% 0.08 8% 92% 144 556 Dominated
BRE-16: Stage IV treatment 95% 0.04 17% 83% 3 11,895 Dominated
BRE-17: Treatment all stages 95% 0.12 18% 82% 568 213 Dominated
BRE-18: Optimal program 95% 0.29 24% 76% 2,452 117 119
Share